Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis

BMC Microbiology

Volumn 10, Issue , 2010, Pages

  Ravindran, Rajesh ^a,b   Bhowmick, Sudipta ^a,c   Das, Amrita ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b EMORY UNIVERSITY   (United States)

^c Dr Kanailal Bhattacharyya College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 4; LEISHMANIA VACCINE; LIPOSOME; PHOSPHORYL LIPID A; TREHALOSE DICORYNOMYCOLATE; UNCLASSIFIED DRUG; VACCINE; 6,6' DICORYNOMYCOLYL TREHALOSE; 6,6'-DICORYNOMYCOLYL TREHALOSE; CORD FACTOR; DRUG DERIVATIVE; IMMUNOLOGICAL ADJUVANT; LIPID A; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; LEISHMANIA DONOVANI; LIVER PROTECTION; MOUSE; NONHUMAN; PROMASTIGOTE; SELF EVALUATION; SPLEEN; TH1 CELL; TH2 CELL; TREATMENT RESPONSE; VACCINATION; VISCERAL LEISHMANIASIS; ANIMAL; BLOOD; IMMUNOLOGY; TIME;

ANIMALIA; LEISHMANIA DONOVANI; MURINAE; MUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BCG VACCINE; CORD FACTORS; FEMALE; IMMUNITY, HUMORAL; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; LIPID A; MICE; TIME FACTORS;

EID: 77955706115     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-10-181     Document Type: Article

References (51)

1. Leishmaniasis: current situation and new perspectives. P Desjeux, Comp Immunol Microbiol Infect Dis 2004 27 305 318 10.1016/j.cimid.2004.03.004 15225981
2. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? F Chappuis S Sundar A Hailu H Ghalib S Rijal RW Peeling J Alvar M Boelaert, Nat Rev Microbiol 2007 5 873 882 10.1038/nrmicro1748 17938629 (Pubitemid 47578388)
3. Recent developments in leishmaniasis vaccine delivery systems. S Bhowmick N Ali, Expert Opin Drug Deliv 2008 5 789 803 10.1517/17425247.5.7.789 18590463
4. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovisBCG. KA Heldwein MD Liang TK Andresen KE Thomas AM Marty N Cuesta SN Vogel MJ Fenton, J Leukoc Biol 2003 74 277 286 10.1189/jlb.0103026 12885945
5. Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guerin by Flt3-ligand generated dendritic cells. F von Meyenn M Schaefer H Weighardt S Bauer CJ Kirschning H Wagner T Sparwasser, Immunobiology 2006 211 557 565 10.1016/j.imbio.2006.05.004 16920494
6. Towards improved understanding of protective mechanisms induced by the BCG vaccine. B Villarreal-Ramos, Expert Rev Vaccines 2009 8 1531 1534 10.1586/erv.09.109 19863244
7. Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. LL Smrkovski CL Larson, Infect Immun 1977 16 249 257 873609
8. The effect of BCG on experimental cutaneous leishmaniasis in mice. J Weintraub FI Weinbaum, J Immunol 1977 118 2288 2290 864260
9. First generation leishmaniasis vaccines: a review of field efficacy trials. S Noazin F Modabber A Khamesipour PG Smith LH Moulton K Nasseri I Sharifi EA Khalil ID Bernal CM Antunes MP Kieny M Tanner, Vaccine 2008 26 6759 6767 10.1016/j.vaccine.2008.09.085 18950671
10. New horizons in adjuvants for vaccine development. SG Reed S Bertholet RN Coler M Friede, Trends Immunol 2009 30 23 32 10.1016/j.it.2008.09.006 19059004
11. + T cells. GG Chikh S Kong MB Bally JC Meunier MP Schutze Redelmeier, J Immunol 2001 167 6462 6470 11714813
12. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. T Nakanishi J Kunisawa A Hayashi Y Tsutsumi K Kubo S Nakagawa M Nakanishi K Tanaka T Mayumi, J Control Release 1999 61 233 240 10.1016/S0168-3659(99)00097-8 10469918
13. Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. M Rao CR Alving, Adv Drug Deliv Rev 2000 41 171 188 10.1016/S0169-409X(99)00064-2 10699313
14. Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens. T Mazumdar K Anam N Ali, J Parasitol 2005 91 269 274 10.1645/GE-356R1 15986599
15. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. F Afrin N Ali, Infect Immun 1997 65 2371 2377 9169776
16. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. S Bhowmick R Ravindran N Ali, Vaccine 2007 25 6544 6556 10.1016/j.vaccine.2007.05. 042 17655984
17. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. S Bhowmick R Ravindran N Ali, Infect Immun 2008 76 1003 1015 10.1128/IAI.00611-07 18195029
18. Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. S Bhowmick N Ali, PLoS One 2009 4 5820 10.1371/journal.pone.0005820 19503834
19. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? D McMahon-Pratt J Alexander, Immunol Rev 2004 201 206 224 10.1111/j.0105-2896.2004.00190.x 15361243
20. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. CR Engwerda ML Murphy EJ Cotterell Sara C Smelt Sara PM Kaye, Eur J Immunol 1998 28 669 680 10.1002/(SICI)1521-4141(199802)28:02<669::AID-IMMU669>3.0.CO;2-N 9521077
21. Differential production of Th1 and Th2-derived cytokines does not determine the genetically controlled or vaccine induced rate of cure in murine visceral leishmaniasis. PM Kaye AJ Curry JM Blackwell, J Immunol 1991 146 2763 2770 1901883
22. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. PC Melby J Yang W Zhao LE Perez J Cheng, Infect Immun 2001 69 4719 4725 10.1128/IAI.69.8.4719-4725.2001 11447143
23. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. GD Miralles MY Stoeckle DF McDermott FD Finkelman HW Murray, Infect Immun 1994 62 1058 1063 8112840
24. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. HW Murray J Hariprashad RL Coffman, J Exp Med 1997 185 867 874 10.1084/jem.185.5.867 9120392
25. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. A Satoskar H Bluethmann J Alexander, Infect Immun 1995 63 4894 4899 7591152
26. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. J Alexander KC Carter N Al-Fasi A Satoskar F Brombacher, Eur J Immunol 2000 30 2935 2943 10.1002/1521-4141(200010)30:10<2935::AID- IMMU2935>3.0.CO;2-Q 11069076
27. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. T Mazumdar K Anam N Ali, Vaccine 2004 22 1162 1171 10.1016/j.vaccine.2003.09.030 15003644
28. Isotype profiles of Leishmania donovani-infected BALB/c mice: preferential stimulation of IgG2a/b by liposome-associated promastigotes antigens. F Afrin N Ali, J Parasitol 1998 84 743 748 10.2307/3284581 9714204
29. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani. S Bhowmick T Mazumdar R Sinha N Ali, J Control Release 2010 141 199 207 10.1016/j.jconrel.2009.09.018 19818373
30. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. MR Jaafari A Badiee A Khamesipour A Samiei D Soroush MT Kheiri F Barkhordari WR McMaster F Mahboudi, Vaccine 2007 25 6107 6117 10.1016/j.vaccine.2007.05.009 17629372
31. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. RX Armijos MM Weigel M Calvopina A Hidalgo W Cevallos J Correa, Vaccine 2004 22 1320 1326 10.1016/j.vaccine.2003.06.002 15003662
32. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. EA Khalil AM El Hassan EE Zijlstra MM Mukhtar HW Ghalib B Musa ME Ibrahim AA Kamil M Elsheikh A Babiker F Modabber, Lancet 2000 356 1565 1569 10.1016/S0140- 6736(00)03128-7 11075771
33. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis. P Tripathi SK Gupta S Sinha S Sundar A Dube S Naik, Scand J Immunol 2008 68 492 501 10.1111/j.1365-3083.2008.02171.x 18803606
34. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis. S Kumari M Samant P Misra P Khare B Sisodia AK Shasany A Dube, Vaccine 2008 26 5700 5711 10.1016/j.vaccine.2008.08.021 18762224
35. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. WR Santos VM de Lima EP de Souza RR Bernardo M Palatnik CB Palatnik de Sousa, Vaccine 2002 21 30 43 10.1016/S0264-410X(02) 00444-9 12443660
36. Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. T Aebischer M Wolfram SI Patzer T Ilg M Wiese P Overath, Infect Immun 2000 68 1328 1336 10.1128/IAI.68.3.1328-1336.2000 10678945
37. + T cells. RN Coler Y Goto L Bogatzki V Raman SG Reed, Infect Immun 2007 75 4648 4654 10.1128/IAI.00394-07 17606603
38. Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis. H Ghalib F Modabber, Kinetoplastid Biol Dis 2007 6 7 10.1186/1475-9292-6-7 17705861
39. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. ID Vélez K Gilchrist S Martínez JR Ramírez-Pineda JA Ashman FP Alves RN Coler LY Bogatzki SJ Kahn AM Beckmann KD Cowgill SG Reed FM Piazza, Vaccine 2009 28 329 337 10.1016/j.vaccine.2009.10.045 19879995
40. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Y Goto LY Bogatzki S Bertholet RN Coler SG Reed, Vaccine 2007 25 7450 7458 10.1016/j.vaccine.2007.08. 001 17804125
41. Enhanced efficacy and immunogenicity of 78 kDa antigen formulated in various adjuvants against murine visceral leishmaniasis. R Nagill S Kaur, Vaccine 2010 28 4002 4012 10.1016/j.vaccine.2010.01.015 20093205
42. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis. S Bhardwaj RK Vasishta SK Arora, Exp Parasitol 2009 121 29 37 10.1016/j.exppara.2008.09.019 18983842
43. Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J Dietrich R Billeskov TM Doherty P Andersen, J Immunol 2007 178 3721 30 17339470
44. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. A Ghosh WW Zhang G Matlashewski, Vaccine 2001 20 59 66 10.1016/S0264-410X(01)00322-X 11567746
45. Effects of combined BCG and DHEA treatment in preventing the development of asthma. Y Cui IS Choi YA Koh XH Lin YB Cho YH Won, Immunol Invest 2008 37 191 202 10.1080/08820130801967833 18389439
46. Low-dose intraperitoneal Freund's adjuvant: toxicity and immunogenicity in mice using an immunogen targeting amyloid-beta peptide. J Oscherwitz FC Hankenson F Yu K Cease, Vaccine 2006 24 3018 3025 10.1016/j.vaccine.2005.10.046 16307832
47. Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection. S Bhowmick T Mazumdar N Ali, Infect Immun 2009 77 1514 1523 10.1128/IAI.01739-07 19168736
48. The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. OL Wijburg GP van den Dobbelsteen J Vadolas A Sanders RA Strugnell N van Rooijen, Eur J Immunol 1998 28 479 487 10.1002/(SICI)1521-4141(199802)28:02<479::AID-IMMU479>3.0.CO;2-R 9521056
49. Protein measurement with the Folin phenol reagent. OH Lowry NJ Rosebrough AL Farr RJ Randall, J Biol Chem 1951 193 265 275 14907713
50. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. JC Stewart, Anal Biochem 1980 104 10 14 10.1016/0003-2697(80) 90269-9 6892980
51. An eight day method for screening compounds against Leishmania donovani in the golden hamster. LA Stauber EM Franchino J Grun, J Protozool 1958 5 269 273